European guideline for the management of hepatitis B and C virus infections (Q44118049)

30 November 2017

title

European guideline for the management of hepatitis B and C virus infections (English)

1 reference

30 November 2017

M G Brook

1

1 reference

30 November 2017

European Branch of the Internatioanl Union against Sexually Transmitted Infection and the European Office of the World Health Organization

series ordinal

2

1 reference

30 November 2017

publication date

1 October 2001

1 reference

International Journal of STD & AIDS

30 November 2017

published in

1 reference

30 November 2017

volume

12 Suppl 3

1 reference

30 November 2017

page(s)

48-57

1 reference

HBV and HCV infection among non-European Union immigrants in North-East Italy.

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Hepatitis B virus infection in patients attending a genitourinary medicine clinic: risk factors and vaccine coverage

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Risky business: health and safety in the sex industry over a 9 year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Evidence of transmission of hepatitis B virus to spouses from sequence analysis of the viral genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Hepatitis B in a highly active prostitute population: evidence for a low risk of chronic antigenemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Prevention of hepatitis B virus (HBV) infection in health-care workers after accidental exposure: a comparison of two prophylactic schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Clinical presentation of acute viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Risks of chronicity following acute hepatitis B virus infection: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Laboratory diagnosis of human hepatitis viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Evidence that anti-HBc but not HBV DNA testing may prevent some HBV transmission by transfusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Response to hepatitis B vaccination in a primary care setting: influence of HIV infection, CD4+ lymphocyte count and vaccination schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Are booster immunisations needed for lifelong hepatitis B immunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule--results of a post-marketing surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Randomized, comparative trial of 20 micrograms vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Review: protective efficacy of hepatitis B vaccines in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Hepatitis B and Delta virus infection among heterosexuals, homosexuals and bisexual men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Fulminant viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Prevalence of hepatitis B and C markers in the south-east of Spain: an unlinked community-based serosurvey of 2,203 adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Hepatitis B and hepatitis C virus infections: risk factors among drug users in Northwest England.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Hepatitis C: the clinical spectrum of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Hepatitis C virus infection in institutionalized psychiatric patients: possible role of transmission by razor sharing

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Hepatitis C virus infection in family setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Sexual transmission of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Sexual and perinatal transmission of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Hepatitis C virus: evidence for sexual transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Hepatitis C virus infection in spouses of patients with type C chronic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Lack of evidence for the heterosexual transmission of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Sexual and non-sexual intrafamilial spread of hepatitis C virus: intrafamilial transmission of HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

A case-control study of risk factors for sporadic hepatitis C virus infection in the southwestern United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Risk factors for acquisition of hepatitis C virus infection in blood donors: results of a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Increased transmission of vertical hepatitis C virus (HCV) infection to human immunodeficiency virus (HIV)-infected infants of HIV- and HCV-coinfected women

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Unexplained hepatitis C virus antibody seroconversion in established blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

The impact of diagnosis of hepatitis C virus on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

High rate of chronicity in HCV infection determined by antibody confirmatory assay and PCR in 4110 patients during long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Impact of alcohol on the histological and clinical progression of hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Diagnosis of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories?

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

French consensus conference on hepatitis C: screening and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Epidemiology of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Prospective investigation of transfusion transmitted infection in recipients of over 20 000 units of blood. TTI Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Syringe exchange and risk of infection with hepatitis B and C viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Accidental transmission of HCV and treatment with interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Factors predictive of a beneficial response to therapy of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Predictors of sustained response to alpha interferon therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Should patients with early loss of serum HCV-RNA during alpha interferon therapy for chronic hepatitis C be treated for 6 or 12 months?

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Low risk of vertical transmission of hepatitis C virus by breast milk

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Twelve-year follow-up of a prospective randomized trial of hepatitis b recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2F0956462011923930

21 January 2018

Identifiers

DOI

10.1258/0956462011923930

1 reference

30 November 2017

1 reference